Analytical Data
-
Gene name
AIG1
- Application
-
Alternative Names
A2LD1; AIG 1; AIG-1; AIG1; AIG1_HUMAN; Androgen induced 1; Androgen induced protein (AIG-1); Androgen induced protein (AIG-1); C-terminus truncated; Androgen-induced gene 1 protein; dJ95L4.1; DKFZp686F03136; FLJ10485; GGACT; RP1 95L4.1
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NVV5
-
Expression Region
60-87aa
-
Molecular Weight
30.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AIG1 (Apoptosis Inhibitor of Growth 1) is a protein implicated in various cellular processes, particularly in the regulation of apoptosis and cell growth. Its role is especially significant in cancer biology, where dysregulation of apoptotic pathways often leads to tumorigenesis. Research on AIG1 has revealed its potential as a biomarker for cancer progression and a target for therapeutic interventions. The protein is known to interact with several key molecular pathways, influencing cell survival and proliferation. As scientists delve deeper into its structure and function, AIG1 has emerged as a pivotal subject in the quest to understand the molecular mechanisms underlying cancer development. Recombining AIG1 might offer insights into its functional domains, allowing us to explore its specific interactions and mechanisms of action. The study of recombinant AIG1 protein could therefore lead to innovative strategies for cancer treatment by either restoring its normal function in tumor-suppressive pathways or by inhibiting its detrimental effects in cancers where it is overexpressed. The ongoing research holds promise for developing novel therapeutic approaches that leverage AIG1’s regulatory role in apoptosis and growth, ultimately aiming to improve outcomes in cancer therapies.
